Top25-SA-Banner

SenesTech (SNES): Don’t Stop Me Now!


SenesTech (NASDAQ:SNES) shares are shooting up 25% faster than Jack’s magic bean sparking right into a giant beanstalk. The reason? The company announced that it has partnered with Pestmaster Services, a premier provider of integrated pest management services, to deploy SenesTech’s fertility control product ContraPest in California, once approval of ContraPest is final.

“We have been preparing this plan for some months, collecting sales leads, reviewing potential customer lists and conducting internal training. Now it is time to execute the plan,” said Dr. Loretta P. Mayer, co-Founder and CEO of SenesTech.

“We have reviewed our existing projects, and we know exactly which customers would benefit from ContraPest in their integrated pest management plan. We also can now approach new customers and offer to do site assessments, and to determine if ContraPest would be right for them,” said Jeff Van Diepen, President and Founder of Pestmaster Services.

SenesTech is on track for its third straight session of gains, skyrocketing nearly 410%. The company announced on Monday that the California Department of Pesticide Regulation (CDPR) has proposed to register ContraPest for use in California, sending investors into a frenzy.

This proposed action will be posted for thirty days. With approval, the Company will then be able to market and sell ContraPest throughout California, which is one of the largest state markets for pest control.

California consistently leads the way with respect to innovative and environmentally sensitive policies, and California consumers can be the most demanding of the products they buy and use – the products must be effective, they must be as safe as possible, they must be ethical, and they must pose the least burden on the planet. These are the qualities that we are committed to and evident in our design of ContraPest. I expect this will be a great market for ContraPest, with rapid adoption, as the California consumers are always ahead of the curve,” said Dr. Loretta P. Mayer, co-Founder and CEO of SenesTech.